Effects of glucocorticoid treatment on bone strength
- 27 January 2010
- journal article
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 28 (5) , 532-539
Abstract
Glucocorticoids (GCs) are prescribed for the treatment of several diseases, but their long-term use causes osteoporosis. Current research suggests that GCs suppress the canonical Wnt/β pathway, resulting in decreased expression of critical bone proteins. This study examined how bone structure and strength of high bone mass (HBM) mice and low density lipoprotein receptor-related protein 5 (LRP5) knockout (KO+/−) mice are affected by GC treatment in comparison to wild-type (WT) mice, and if changes were specific to either trabecular or cortical bone. Mice were treated with either prednisone or placebo. The femurs and L4 vertebral bodies were analyzed by micro-CT for structure and mechanically tested to determine strength and apparent material strength properties. Differences in all measured variables corresponding to GC treatment and genotype were tested using two-way ANOVA. GC treatment caused decreased structural strength parameters, weakened apparent material strength properties, and disruption of bone structure in HBM, but not LRP5+/− or WT, mice. Despite treatment-related loss, trabecular bone structure and strength remained elevated as compared to LRP5+/− and WT mice. In HBM femurs, both cortical and trabecular structure, but not strength parameters, were negatively affected by treatment. In HBM vertebral bodies, both structural and strength parameters were negatively affected by treatment.Keywords
This publication has 38 references indexed in Scilit:
- Prevention of glucocorticoid‐induced bone loss in mice by inhibition of RANKLArthritis & Rheumatism, 2009
- Management of glucocorticoids-induced osteoporosis: role of teriparatideTherapeutics and Clinical Risk Management, 2009
- Glucocorticoid induces apoptosis of osteoblast cells through the activation of glycogen synthase kinase 3βJournal of Bone and Mineral Metabolism, 2008
- Parathyroid hormone treatment for osteoporosisCurrent Opinion in Endocrinology, Diabetes and Obesity, 2008
- Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the DuodenumCell, 2008
- Glucocorticoid‐induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralizationArthritis & Rheumatism, 2008
- Prednisolone-induced Ca2+malabsorption is caused by diminished expression of the epithelial Ca2+channel TRPV6American Journal of Physiology-Gastrointestinal and Liver Physiology, 2007
- Alendronate or Alfacalcidol in Glucocorticoid-Induced OsteoporosisNew England Journal of Medicine, 2006
- Inhibition of cortical and cancellous bone formation in glucocorticoid-treated OVX sheepBone, 2005
- Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosisBiochemical and Biophysical Research Communications, 2004